A recent study demonstrates that intense pulsed light (IPL) therapy significantly improves tear film stability and reduces ocular surface inflammation in patients with dry eye disease (DED). A regimen of three IPL sessions is shown to outperform two sessions in key clinical parameters, suggesting IPL's role as a core strategy in managing evaporative DED.
Background
Dry eye disease (DED) is a common condition that can significantly impact quality of life. Intense pulsed light (IPL) therapy has emerged as a promising treatment, particularly for patients with meibomian gland dysfunction (MGD). Understanding the optimal treatment regimen and the biological mechanisms involved is crucial for enhancing patient outcomes.
IPL therapy improves tear film stability and meibomian gland performance.
Three IPL sessions yield better outcomes than two sessions in key clinical parameters.
At 12 weeks, NITBUT increased significantly more in the three-session group.
Only the three-session regimen resulted in a significant rise in the tear biomarker lymphotoxin-alpha (LT-α).
Both groups showed symptom improvement, but objective measures continued to improve in the three-session group.
Clinical Implications
Clinicians should consider IPL therapy as a primary treatment option for patients with evaporative DED, particularly those with MGD. A regimen of three sessions may provide superior long-term benefits compared to fewer sessions, emphasizing the need for tailored treatment plans.
Conclusion
The findings support the integration of IPL therapy into standard care for DED, highlighting its potential to address both symptoms and underlying biological mechanisms.
